Novo Nordisk: Wegovy Impresses in Heart Protection - Revenue Exceeds the €10 Billion Mark!
Reading Time: 2 minutes
Recent study data recently published by Novo Nordisk show that Wegovy, containing the active ingredient Semaglutide, reduces the risk of heart attack, stroke, or sudden cardiac death by 57% compared to Eli Lilly's Tirzepatide. The analysis of over 21,000 patients with overweight or obesity and existing cardiovascular diseases highlighted the difference. Severe events occurred in only 0.1% of patients taking Wegovy, while it was 0.4% for Tirzepatide. Chance of reimbursement by health insurers increases The markets reacted immediately. Novo Nordisk's...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
